I am working as a Research Officer at Queensland Alliance for Agriculture and Food Innovations,, University of Queensland, Australia. My research focuses on infectious diseases of animals. In my early career, I worked on the detection and immunology of bovine mastitis. The first ever mastitis vaccine for dairy animals commercialized in Pakistan was a high-impact outcome of my M.Phil research work. My PhD research focused on anthelmintic resistance in helminths, including detection of anthelmintic resistance and investigating the possible mechanisms associated with anthelmintic resistance. I am further interested to continue my research on host parasite interactions and effects of different drugs on parasite and host immune system. I also find myself enthusiastic to work on Clinical Parasitology, anti-parasitic drugs resistance and drug discovery. I am working on developing phenotypic techniques for diagnosing the tick susceptible and resistant hosts, as well as investigating the genetic biomarkers for ticks, buffalo flies and fly lesions susceptibility in cattle.
Primary Affiliation: University of Queensland - Brisbane, Queensland , Australia
Mastitis is a one of the major diseases of dairy animals. Staphylococcus aureus is the most common microorganism associated with this dairy scourge. Cure rates of mastitis associated with this pathogen are appallingly low. Biofilm is an important virulence factor and immunogenic structure of S. aureus that makes it resistant to phagocytosis and antibiotics. Reports on the efficacy of vaccine prepared from a biofilm producing S. aureus are infrequent. The present study was designed to evaluate the role of a bacterin-toxoid prepared from a strong biofilm producing S. aureus in effective immunization of rabbits. The strong biofilm
producing S. aureus selected from 64 isolates of staphylococci was used to prepare bacterin-toxoid and aluminum hydroxide gel was added as an adjuvant. The vaccine was evaluated in rabbits by challenge protection assay and humoral immune response. The mortality rates in control and vaccinated groups were 80% and 10% at day 7 post challenge and 100% and 20% at day 15 post challenge, respectively. Serum antibody titer (GMT) was significantly higher (294.0) in vaccinated group as compared to control group of rabbits (2.63) at day 45. The results showed that the vaccine has significantly elicited humoral immune response in rabbit and developed protective efficacy against new infections.